drugset / Trial / NCT07018050
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and Pomalidomide, and QLS32105(SC) in combination with Bortezomib and Lenalidomide.
Timeline
- Start
- 2025-09-12
- Primary completion
- 2027-11
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Subcutaneous |
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Pomalidomide | Other / unclassified | — | Oral |
| Subject | QL2109 | Monoclonal antibody | — | Subcutaneous |
| Subject | QLS32015 | Unknown | — | Subcutaneous |
| Background | Dexamethasone | Small molecule | — | Oral |